Henry Schein account plan
global healthcare products services
At a glance
Henry Schein distributes health care products and software to dental and medical practices, with $13,184 million FY2025 sales and about 25,000 employees.
Henry Schein (Nasdaq: HSIC), headquartered in Melville, New York, provides health care products, specialty products, software and services primarily to office-based dental and medical practitioners. It serves more than one million customers from 38 distribution centers and 17 manufacturing facilities, with operations or affiliates in 34 countries and territories. FY2025 net sales were $13,184 million (+4.0%), operating income $653 million and net income attributable to Henry Schein $398 million. It employs about 25,000 people, and KKR invested $250 million in May 2025 under a strategic partnership.
Business units
Global Distribution and Value-Added Services
84.5% of FY2025 net sales ($11,138 million)Distributes national and corporate brand consumables, equipment and technical services to dental and medical practices, plus financing, consulting and practice transition services. Dental merchandise grew 7.0% in Q3 2026 while medical grew 1.1%. Led by Andrea Albertini, CEO Global Distribution and Technology.
Global Specialty Products
11.7% of FY2025 net sales ($1,544 million)Manufactures and sells dental implants, biomaterials, orthodontics, endodontics and orthopedics, with a 54.8% gross margin in FY2025. Q3 2026 sales rose 6.1% on value and premium implants, including the new Versalis implant. Led by Tom Popeck, CEO Henry Schein Products Group.
Global Technology (Henry Schein One)
5.1% of FY2025 net sales ($675 million)Practice management, revenue cycle management, AI and patient engagement software for dental practices, including Dentrix, Dentrix Ascend and Dentally. About 90% of revenue is recurring, and almost 13,500 cloud subscribers are adding about 200 net new per month.
Strategic priorities
- Practice improvement platform
- CEO Fred Lowery wants Henry Schein positioned less as a distributor and more as the practice improvement platform for its customers within three years.
- Value creation programme
- More than $200 million of operating income improvement, including a $125 million run rate by the end of 2026, through outsourcing of finance and customer service, centralised indirect procurement and data-driven pricing.
- Higher-growth, higher-margin mix
- Software, specialty products and own brands are projected at 50% of total operating income in 2026, with a goal of over 50% by 2027.
- BOLD+1 strategy
- The 2025-2027 plan builds software, specialty and services businesses, operationalises One Distribution, leverages One Schein and drives digital transformation.
- AI in dental software
- AI-enabled packages Ascend Pro and Ascend Accelerate cover clinical documentation, eligibility, claims and imaging, and an MCP layer will let practices query their data with AI agents.
Latest results
In Q3 2026 (quarter ended September 26, 2026) net sales rose 4.0% to $3,471 million, with internal growth of 3.1%. U.S. dental merchandise grew 8.6%, specialty products 6.1% and technology 5.2%, while medical grew only 1.1%. Gross margin rose to 31.8% from 30.7%, helped by a $28 million net benefit from tariff refunds, and diluted EPS was $1.06 (vs $0.84). Nine-month sales were $10,297 million (+5.6%). FY2026 guidance was raised to non-GAAP EPS of $5.50-$5.56 with sales growth of 4.5%-5.5%, then recast to $5.42-$5.48 on November 16, 2026 after excluding remeasurement gains.
Investments and deals
- Acquisitions
- 2025 acquisitions across all three segments totalled $392 million of consideration; 2026 acquisitions in distribution and specialty products totalled $93 million, including a majority stake in S.I.N. 360.
- Global outsourcing and shared services
- A global outsourcing provider was selected for finance and customer service and should deliver more than half of the G&A savings; 2027 adds broader outsourcing, AI for productivity and new supply chain software.
- Restructuring plan
- The 2024 restructuring plan runs to end-2027, with charges of $105 million in 2025 and $63 million in the first nine months of 2026.
- Share buybacks
- $450 million repurchased year to date in 2026, with about $330 million of authorisation left.
Challenges and risks
- Leadership transition
- Stanley Bergman retired as CEO on March 1, 2026 and the CFO changed on November 4, 2026; the 10-Q flags these transitions as a risk.
- Weak medical segment
- Medical grew only 1.1% in Q3 2026 as point-of-care diagnostic tests and respiratory vaccines fell.
- Tariffs and Medicaid cuts
- Tariffs and trade policy remain a risk, and the One Big Beautiful Bill Act is expected to reduce Medicaid enrolment and funding.
- Cybersecurity
- The October 2023 incident disrupted North American and European distribution; cybersecurity stays a named risk.
- Competition and rising debt
- Competition from Patterson, Benco, McKesson, Medline and implant makers continues, and total debt rose to $3,524 million at September 26, 2026.
What leadership says
“Our strategy is translating into stronger financial results. We are gaining share in key businesses, improving our portfolio mix, maintaining a disciplined approach to capital allocation, and realizing the benefits of our value creation initiatives”
“Coming soon is the launch of an MCP layer that enables practices to query their own data with AI applications and agents.”
“We're seeing primarily volume, which I think in the past we've seen primarily price.”
“excited about the meaningful opportunities ahead to drive growth, expand margins and create long-term shareholder value.”
Where a supplier can help
- Business process outsourcing and shared services
- The value creation programme relies on outsourcing finance and customer service and building shared services, which opens doors for BPO, automation and change-management providers.
- Indirect procurement and pricing tools
- A new procurement office centralising indirect spend and data-driven pricing create demand for spend analytics and pricing software.
- Supply chain software
- New supply chain software to cut inventory is a stated 2027 initiative across 38 distribution centers.
- AI and data partners for Henry Schein One
- AI-enabled Dentrix Ascend packages and the MCP layer point to partnerships in clinical AI, voice documentation, claims automation and data infrastructure.
- Cybersecurity
- The 2023 incident and cybersecurity as a named risk make security services relevant across distribution and the software business.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Henry Schein?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Henry Schein, Inc. Annual Report on Form 10-K for fiscal year 2025 (year ended December 27, 2025)
- Henry Schein describes itself as the world's largest provider of health care products and services primarily to office-based dental and medical practitioners: more than one million customers, more than 25,000 employees (approximately 48% in the U.S.), operations or affiliates in 34 countries and territories, more than 300,000 products, 38 distribution centers and 17 manufacturing facilities.
- FY2025 net sales were $13,184 million (+4.0%; internal growth 2.6%, acquisitions 0.9%, FX 0.5%); operating income $653 million; net income attributable to Henry Schein $398 million; diluted EPS $3.27 (vs $3.05).
- Three segments: Global Distribution and Value-Added Services ($11,138 million, 84.5% of sales; dental 52.0%, medical 32.5%), Global Specialty Products ($1,544 million, 11.7%; implants, biomaterials, endo, ortho, orthopedics) and Global Technology ($675 million, 5.1%; Henry Schein One practice management software).
- Margin mix: gross margin 25.0% in distribution, 54.8% in specialty products and 67.7% in technology; segment operating income $680 million, $242 million and $180 million respectively.
- Strategy is the 2025-2027 BOLD+1 plan (build software/specialty/services, One Distribution, One Schein, digital transformation) plus acquisitions; 2025 acquisitions totalled $392 million of consideration. The 2024 restructuring plan (charges of $105 million in 2025) runs to end-2027.
- Governance shift: KKR invested $250 million (May 2025) under a Strategic Partnership Agreement with two board designees and a cap raised to 19.9%; Stanley M. Bergman retires as CEO on March 1, 2026 and Frederick M. Lowery becomes CEO on March 2, 2026.
- Capital: total debt rose to $3,107 million from $2,536 million; $780 million left for buybacks after new authorisations of $500 million and $750 million in 2025.
- Key risks: supplier dependence (top 10 distribution suppliers about a quarter of purchases), tariffs, Medicaid cuts in the One Big Beautiful Bill Act, cybersecurity (October 2023 incident), competition from Patterson, Benco, McKesson, Medline, Straumann, Envista and others.
- Henry Schein Form 10-Q for the quarter ended September 26, 2026 (Q3 2026)
- Q3 2026 net sales $3,471 million (+4.0%: internal 3.1%, acquisitions 0.7%, FX 0.2%); operating income $193 million (vs $164 million); net income attributable to Henry Schein $119 million; diluted EPS $1.06 (vs $0.84).
- Nine months 2026: net sales $10,297 million (+5.6%), operating income $546 million, diluted EPS $2.80 (vs $2.42).
- Dental drove growth: Q3 Global Dental Merchandise $1,295 million (+7.0%, internal 5.1%); Dental Equipment $449 million (+2.3%); Medical $1,138 million (+1.1%) as Home Solutions growth was offset by lower point-of-care tests and respiratory vaccines.
- Global Specialty Products Q3 $391 million (+6.1%, value and premium implants); Global Technology $181 million (+5.2%, internal 6.5%, cloud practice management and revenue cycle management).
- Gross margin rose to 31.8% from 30.7%, helped by a $28 million net benefit from IEEPA tariff refunds in the quarter, mix and value creation initiatives; more refunds expected in Q4 2026.
- 2024 restructuring plan continues to end-2027 ($22 million in Q3, $63 million in nine months).
- Total debt $3,524 million at September 26, 2026 (vs $3,107 million at year end); $330 million of buyback authorisation left after $6.4 billion repurchased since 2003.
- CFO change: Ronald N. South hands over to Emmanuel Caprais on November 4, 2026.
- Henry Schein Reports Strong 2026 Third Quarter and Raises FY2026 Guidance (Q3 2026 earnings release)
- Q3 2026 sales $3.5 billion, +4.0% (internal 3.1%); GAAP diluted EPS $1.06 (+26.2%); non-GAAP diluted EPS $1.56 (+13.0%), or $1.37 (+19.1%) excluding a $0.19 tariff-refund benefit and the prior-year $0.23 remeasurement gain.
- U.S. dental merchandise sales grew 8.6%, which CEO Fred Lowery attributes "primarily by volume in a stable market"; Global Dental merchandise +7.0%, equipment +2.3%, Medical +1.1%, Value-Added Services -4.8%.
- Global Specialty Products +6.1% (internal 3.4%); Global Technology +5.2% (internal 6.5%).
- Adjusted EBITDA $321 million (vs $295 million), margin 9.24%; nine-month Adjusted EBITDA $898 million.
- Nine months: sales $10.3 billion (+5.6%), GAAP EPS $2.80 (+15.7%), non-GAAP EPS $4.14 (+14.0%).
- FY2026 guidance raised: non-GAAP EPS $5.50-$5.56 (from $5.29-$5.39), sales growth 4.5%-5.5% unchanged, Adjusted EBITDA growth high-single-digits; Q4 includes "targeted and limited growth-investments".
- Buybacks of $125 million in Q3 and $450 million year to date; about $330 million authorisation left.
- Note: on November 16, 2026 the company recast non-GAAP measures to exclude remeasurement gains, which moved FY2026 EPS guidance to $5.42-$5.48 (separate release, not this document).
- Q3 2026 Henry Schein, Inc. Earnings Call (edited transcript)
- CEO Fred Lowery: U.S. dental merchandise grew 8.6% (7% internal), "driven primarily by volume in a stable market", with share gains in private practices and emerging DSOs, own-brand products and exclusives such as Curodont.
- Value creation unchanged: more than $200 million of operating income improvement, including a $125 million run rate by end of 2026; Lowery says this builds toward double-digit EPS growth in 2027.
- Three priorities: accelerate growth, simplify the business (delayering, shared services, outsourcing, centralised indirect procurement, pricing and margin tools), and more rigour and discipline in execution and capital allocation.
- Q4 includes limited growth investments to win new customers, raise share of wallet and convert episodic customers.
- Henry Schein One: almost 13,500 Dentrix Ascend and Dentally cloud subscribers, about 200 net new per month; AI-enabled packages (Ascend Pro, Ascend Accelerate).
- Higher-growth, higher-margin businesses projected at 50% of total operating income in 2026; Home Solutions grew double digits; Versalis implant launched in the value segment.
- CFO Ron South: Q3 non-GAAP operating margin 8.03%; FY2026 non-GAAP EPS guidance $5.50-$5.56; Adjusted EBITDA growth high single digits on a 2025 base of $1.1 billion; Emmanuel Caprais becomes CFO November 4.
- Q2 2026 Henry Schein Inc Earnings Call (edited transcript)
- First months as CEO: Fred Lowery says he has "an increased conviction" that Henry Schein can improve revenue growth and profitability and become "the practice improvement platform" for customers rather than just a distributor.
- Priorities: accelerating growth, simplifying the business, driving operational rigor and deepening customer relationships.
- Value creation: at least $200 million of operating income improvement over the next few years; a global outsourcing provider for finance and customer service is expected to deliver more than half of the G&A savings; a procurement office and data-driven pricing support gross profit. In 2026 about 40% of the benefit from gross profit, 60% from G&A.
- Henry Schein One: about 90% recurring revenue; average monthly revenue about $500 per customer vs about $800 for Dentrix Ascend; almost 13,000 cloud customers; June a record month; AI clinical workflow launched and an MCP layer announced to let practices query their data with AI agents.
- Higher-growth, higher-margin businesses almost 50% of operating income, with a goal of over 50% by 2027; own brands growing almost twice as fast as other merchandise.
- Q2 2026: sales $3.5 billion (+6.7%, internal 4.6%), non-GAAP EPS $1.27 (+15.5%), Adjusted EBITDA $288 million (+12.7%); FY2026 guidance raised to sales growth 4.5%-5.5% and non-GAAP EPS $5.29-$5.39.
- Leadership team changes removed a layer and folded supply chain into distribution; three long-serving executives (Michael, Mark and Jim) became senior advisors.
Questions about Henry Schein
What does Henry Schein do?
Henry Schein distributes dental and medical supplies and equipment, makes dental implants and other specialty products, and sells dental practice software through Henry Schein One.
What is Henry Schein's revenue?
FY2025 net sales were $13,184 million, up 4.0%; nine-month 2026 sales were $10,297 million.
How many employees does Henry Schein have?
About 25,000, with operations or affiliates in 34 countries and territories.
Who is Henry Schein's CEO?
Frederick M. (Fred) Lowery became CEO on March 2, 2026, succeeding Stanley M. Bergman, who remains Chairman. Emmanuel Caprais became CFO on November 4, 2026.
What is Henry Schein's strategy?
Accelerate growth, simplify the business and add rigour in execution, aiming for more than $200 million of operating income improvement and a larger share of software, specialty and own-brand profits.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)